logo.png
Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting
August 04, 2021 09:00 ET | Nexstim Oyj
Press release, Helsinki, 4 August 2021 at 4 PM (EEST) Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company")...
researchdrivelogo.jpg
Global Plasma Fractionation Market Set to Grow Immensely due to the Rising Demand for Plasma in the Treatment of Several Illnesses – Exclusive Report [165 Pages] By Research Dive
August 02, 2021 09:05 ET | Research Dive
New York, USA, Aug. 02, 2021 (GLOBE NEWSWIRE) -- According to the latest report by Research Dive, the global plasma fractionation market is anticipated to garner a revenue of $45,803.2 million by...
AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC
July 29, 2021 12:07 ET | AB Science
PRESS RELEASE RESULTS FROM MASITINIB STUDY AB09004 IN MILD TO MODERATE ALZHEIMER’S DISEASE PRESENTED AT THE ANNUAL ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) WITH THE FULL ABSTRACT...
AB Science annonce que les résultats de son étude de phase 3 dans la maladie d’Alzheimer ont été présentés à la AAIC
July 29, 2021 12:07 ET | AB Science
COMMUNIQUE DE PRESSE LES RESULTATS DE L’ETUDE DU MASITINIB AB09004 DANS LES FORMES LEGERES A MODEREES DE LA MALADIE D’ALZHEIMER ONT ETE PRESENTES A LA ALZHEIMER’S ASSOCIATION INTERNATIONAL...
logo.png
Nexstim Receives an NBS System Order from a University Hospital in Germany
July 29, 2021 03:00 ET | Nexstim Oyj
Press release, Helsinki, 29 July 2021 at 10 AM (EEST) Nexstim Receives an NBS System Order from a University Hospital in Germany Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces...
Ochsner Ranked #1 Hospital in Louisiana by U.S. News & World Report for the 10th Consecutive Year
July 27, 2021 10:05 ET | Ochsner Health
New Orleans, LA, July 27, 2021 (GLOBE NEWSWIRE) -- Ochsner Medical Center (OMC), inclusive of Ochsner Medical Center- West Bank Campus and Ochsner Baptist*, has been ranked the #1 hospital in...
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
July 22, 2021 12:10 ET | AB Science
PRESS RELEASE AB SCIENCE TO PRESENT RESULTS FROM ITS PHASE III AB09004 STUDY IN MILD TO MODERATE ALZHEIMER’S DISEASE AT THE WORLD'S LARGEST CONFERENCE FOR ALZHEIMER’S AND DEMENTIA RESEARCH (AAIC...
AB Science annonce qu’un résumé de son étude de phase 3 dans la maladie d’Alzheimer a été sélectionné pour une présentation orale à la Alzheimer’s Association International Conference (AAIC)
July 22, 2021 12:10 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE PRESENTERA LES RESULTATS DE SON ETUDE DE PHASE 3 AB09004 DANS LES FORMES LEGERES A MODEREES DE LA MALADIE D’ALZHEIMER LORS DE LA PLUS GRANDE CONFERENCE MONDIALE SUR LA...
AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
July 19, 2021 12:12 ET | AB Science
PRESS RELEASE LONG-TERM FOLLOW-UP OF 75 MONTHS SHOWED THAT MASITINIB EXTENDED SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS BY 25 MONTHS RELATIVE TO PLACEBO, PROVIDED THAT TREATMENT STARTS EARLY...
AB Science annonce la publication de nouvelles données de survie montrant que le masitinib prolongeait la survie dans la SLA de 25 mois par rapport au placebo
July 19, 2021 12:12 ET | AB Science
COMMUNIQUE DE PRESSE DE NOUVELLES DONNEES À LONG TERME SUR UNE DUREE DE 75 MOIS ONT MONTRÉ QUE LE MASITINIB PROLONGEAIT LA SURVIE DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE DE 25 MOIS PAR RAPPORT AU...